Loading clinical trials...
Loading clinical trials...
DOT Diary (D2): Developing a Mobile App With Combined Automated DOT and Daily Sexual Diary for Monitoring and Improving PrEP Adherence: DOT Diary Optimization Pilot
Conditions
Interventions
Emtricitabine / Tenofovir Disoproxil Oral Tablet
DOT Diary mobile app
Locations
2
United States
Bridge HIV, San Francisco Department of Public Health
San Francisco, California, United States
Emory University, School of Public Health
Atlanta, Georgia, United States
Start Date
February 28, 2018
Primary Completion Date
August 30, 2018
Completion Date
August 30, 2018
Last Updated
October 27, 2021
NCT05613010
NCT07071623
NCT05546931
NCT06576648
NCT06889831
NCT05522647
Lead Sponsor
Public Health Foundation Enterprises, Inc.
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions